Patents Expiring in December 2030
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hisamitsu Pharm Co | SALONPAS | menthol; methyl salicylate | PATCH;TOPICAL | 022029-001 | Feb 20, 2008 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ||||
| Hisamitsu Pharm Co | SALONPAS | menthol; methyl salicylate | PATCH;TOPICAL | 022029-002 | Nov 5, 2012 | OTC | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ||||
| Glaxosmithkline | OJJAARA | momelotinib dihydrochloride | TABLET;ORAL | 216873-001 | Sep 15, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS | ||
| Glaxosmithkline | OJJAARA | momelotinib dihydrochloride | TABLET;ORAL | 216873-002 | Sep 15, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS | ||
| Glaxosmithkline | OJJAARA | momelotinib dihydrochloride | TABLET;ORAL | 216873-003 | Sep 15, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS | ||
| Genentech Inc | ESBRIET | pirfenidone | CAPSULE;ORAL | 022535-001 | Oct 15, 2014 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE | |||
| Genentech Inc | ESBRIET | pirfenidone | CAPSULE;ORAL | 022535-001 | Oct 15, 2014 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | METHOD FOR ADMINISTERING PIRFENIDONE WHILE AVOIDING OR DISCONTINUING CONCOMITANT USE OF A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME INVOLVED IN PIRFENIDONE METABOLISM | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
